Search Subcontracts

COA-019_MQ3W9_2024

Overview

Sub Description
SUPPORT TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. (UNDISCLOSED BY PRIME)
Total Awarded
$814,583.58
Most Recent Award Date
Jan. 1, 2024
Place of Performance
United States
Prime Awardee
Prime Project Title
None
Prime Award

Award Hierarchy

Definitive Contract

75N93020C00020

Subcontract

COA-019_MQ3W9_2024

Related Subcontracts

Subcontracts under the same prime contract

Subcontract History

Disclosed subcontract actions

Prime Contract Details


Prime Status

Period of Performance
7/1/20
Start Date
10/19/25
Current End Date
10/19/25
Potential End Date
98.0% Complete

Obligations
$18.5M
Total Obligated
$18.5M
Current Value
$23.5M
Potential Value
79% Funded

Prime Overview

Original Description
TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES.
NAICS
Not Reported
Pricing
Cost Plus Fixed Fee
Place of Performance
Boulder, CO 80301 United States
Set Aside
None
Extent Competed
Full And Open Competition
Last Modified: 1/1/24